KRAS G12D mutation was present in 23 patients overall – 16 patients in the STS cohort, four patients in the uterine sarcoma cohort, one patient in the bone sarcoma cohort (Ewing sarcoma), one patient in the breast sarcoma cohort (malignant phyllodes tumor), and one patient in the GIST cohort. Here, KRAS is linked to uterine corpus sarcoma.